Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 13/20 | 0.59 |
| ▸ | MMP13 | P45452 | 6/20 | 0.53 |
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211847 | 0.88 | ADAM17 (0.60) | ADAM17MMP13MMP2MMP9MMP3 | |
| SCHEMBL6209950 | 0.87 | ADAM17 (0.62) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6210179 | 0.86 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6209402 | 0.85 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6212434 | 0.84 | ADAM17 (0.63) | ADAM17MMP13MMP2MMP9MMP3 | |
| SCHEMBL4050333 | 0.82 | ADAM17 (0.76) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6210147 | 0.81 | ADAM17 (0.63) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6364828 | 0.80 | ADAM17 (0.55) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6210103 | 0.79 | ADAM17 (0.73) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL6209664 | 0.78 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ASTAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1539740-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ADAM10, ADAM17, TNF | ADAM17 2/4885MMP13 194/4885MMP2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.